Arvinas LLC(US:ARVN) Globenewswire·2025-10-22 20:00Core Insights - Arvinas, Inc. announced the presentation of preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [1] - ARV-806 targets the KRAS G12D mutation, which is prevalent in various solid tumors, indicating a significant unmet medical need [2] - The company is advancing multiple investigational drugs, including ARV-806, through clinical development programs [3] Group 1: ARV-806 Presentation Details - Title of the presentation: Preclinical Activity of ARV-806, a PROTAC KRAS G12D Degrader [1] - Presentation type: Poster presentation, scheduled for October 24, 2025, from 12:30-4pm ET [1] - Poster number: B107, part of Poster Session B [1] Group 2: About ARV-806 - ARV-806 is designed to selectively target and degrade the KRAS G12D mutation, which is the most common mutation of the KRAS protein [2] - The drug is currently in a Phase 1 clinical trial for patients with advanced solid tumors harboring KRAS G12D mutations [2] Group 3: About Arvinas - Arvinas is a clinical-stage biotechnology company focused on developing therapies that utilize the body's natural protein disposal system [3] - The company is also developing other investigational drugs targeting various conditions, including breast cancer and neurodegenerative disorders [3] - Arvinas is headquartered in New Haven, Connecticut [3]